On Friday, H.C. Wainwright maintained a Buy rating for Outlook Therapeutics Inc. (NASDAQ:OTLK) with a steady price target of $30.00, despite the company's lead product candidate, ONS-5010, missing a key endpoint in the NORSE 8 trial. The stock, currently trading at $1.70, has experienced significant pressure, falling over 66% in the past week alone.
According to InvestingPro data, analyst consensus remains strongly bullish with price targets ranging from $9 to $53, suggesting potential upside despite recent setbacks. The firm expressed surprise at the outcome, given the previous NORSE 2 trial results. ONS-5010, aimed to treat wet age-related macular degeneration, did not meet the non-inferiority endpoint at week 8 when compared to ranibizumab.
The NORSE 8 trial's results showed that ONS-5010 did not achieve the pre-specified non-inferiority margin, with a -2.257 Best Corrected Visual Acuity (BCVA) letter difference from ranibizumab, missing the threshold set by the special protocol assessment with the FDA.
With a market capitalization of just $40.21 million and an InvestingPro Financial Health Score rated as 'WEAK', the company faces significant challenges ahead. (InvestingPro subscribers have access to 13 additional key insights about OTLK's financial health and market position.) The lower bound of the range did not meet the -3.5 letter threshold. Despite this, Outlook Therapeutics plans to proceed with a Biologics License Application (BLA) submission in the first quarter of 2025.
ONS-5010 demonstrated a mean change in BCVA at week 8 of +4.2 letters, which was not significantly different from the +6.3 letters improvement observed in the ranibizumab arm. This was based on the intent-to-treat primary dataset. The results were unexpected, especially considering the robust response from the ranibizumab arm, which was not anticipated based on earlier NORSE 2 findings.
H.C. Wainwright noted that ONS-5010 had a generally good tolerance profile, consistent with previous studies. The management of Outlook Therapeutics had based their statistical plan on an assumption of no difference between ONS-5010 and ranibizumab, as seen in the NORSE-2 trial.
Despite the setback in the NORSE 8 trial, H.C. Wainwright reaffirmed their confidence in the potential of ONS-5010 and reiterated their $30 price target for Outlook Therapeutics' shares. The stock's RSI indicates oversold conditions, while the company maintains a moderate debt level with a debt-to-capital ratio of 0.45.
Investors seeking deeper insights into OTLK's valuation metrics and growth potential can access comprehensive analysis through InvestingPro's advanced financial tools and expert research. The firm's outlook remains positive on the stock, signaling its belief in the company's value proposition and the future prospects of its lead product candidate.
In other recent news, Outlook Therapeutics has experienced a series of developments. The company's target price was adjusted by BTIG, reducing it to $9 from the previous $50, while maintaining a Buy rating.
This decision came in the wake of the company's product, ONS-5010, not meeting the 95% confidence interval threshold for the primary endpoint in the NORSE EIGHT trial. Despite this, the company plans to resubmit the Biologics License Application for ONS-5010 in 2025, based on expected data from the NORSE EIGHT study.
Outlook Therapeutics also reported preliminary results from the NORSE EIGHT clinical trial, which did not meet its non-inferiority endpoint at week 8. However, the data indicated an improvement in vision and confirmed the treatment's biologic activity and safety. H.C. Wainwright analysts have maintained a Buy rating on Outlook Therapeutics, expressing a positive outlook toward these developments.
Furthermore, patient enrollment for the NORSE EIGHT clinical trial has been completed, marking a significant step toward the potential resubmission of a Biologics License Application for ONS-5010 in the United States. The company is also preparing for a 2025 launch in Europe, where ONS-5010 has already received approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.